|

Phase II Study of Daily Adaptive Radiotherapy for Submandibular Gland-sparing in Head and Neck Cancer

RECRUITINGN/ASponsored by University Health Network, Toronto
Actively Recruiting
PhaseN/A
SponsorUniversity Health Network, Toronto
Started2025-10-15
Est. completion2029-10-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07348887

Summary

This is a randomized, single centre, single blinded prospective study comparing the standard of care imaging guided radiation therapy and daily adaptive radiotherapy (ART) for submandibular gland-sparing in head and neck cancer

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years
* Histologically proven Squamous Cell carcinoma of head and neck
* Bilateral neck being treated
* At least one level 1b not being treated electively and with no target structure, other than elective level II/III, \<1cm to spared SMG
* ECOG PS 0-2
* Planned for curative (chemo)radiotherapy
* Able to receive and understand verbal and written information regarding study and able to give written informed consent
* Be able to lie comfortably on back and to wear immobilization for up to 1 hour

Exclusion Criteria:

* As judged by investigator evidence of systemic disease that makes unsuitable for study
* Pregnancy
* Underlying salivary dysfunction prior to treatment judged by investigator to affect likelihood of benefit from ART

Conditions2

CancerSquamous Cell Cancer of Head and Neck (SCCHN)

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.